Tradestie Institutional Equity Comparison Engine
XNCR vs CGON โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
XNCR Overall Edge
XNCR Captures Institutional Edge (4โ0 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Xencor, Inc. (XNCR) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, XNCR trades at 68.0x Forward P/E with -72.7% operating margin (+454.9% YoY revenue) versus CGON at N/M Forward P/E and -4293.5% operating margin (-3.7% YoY). In options structure, XNCR sits in BREAKOUT (10th %ile IV; Dealer Gamma Walls on Pro) against CGON sits in CONSOLIDATION (85th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
XNCR
XNCR 68.0x vs CGON N/M Fwd P/E
Growth & Margin Winner
XNCR
Op Margin -72.7% vs -4293.5% ยท YoY +454.9% vs -3.7%
Momentum & Technical Winner
XNCR
1Y +154.5% vs +124.9% ยท 52W Pos 84% vs 84%
Options & Structure Winner
XNCR
BREAKOUT (10th %ile IV) vs CONSOLIDATION (85th %ile IV)
XNCR
NASDAQ
Xencor, Inc.
Pharmaceutical Preparations
$35.61
-3.99% 1D
Market Cap
$2.9B
1M Return
+55.84%
1Y Return
+154.54%
Forward P/E
68.0x
Unified AI Score
29.6 / 100
SELL
Tech 50.0
Fund 32.0
Flow 66.0
Mom 40.0
CGON
NASDAQ
CG Oncology, Inc. Common stock
Biological Products, (No Disgnostic Substances)
$84.94
+14.16% 1D
Market Cap
$6.3B
1M Return
+41.91%
1Y Return
+124.93%
Forward P/E
N/M
Unified AI Score
45.0 / 100
HOLD
Tech 15.0
Fund 44.0
Flow 69.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
XNCR +154.54%
CGON +124.93%
Spread: +29.61 pp (XNCR Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | XNCR Revenue | CGON Revenue | XNCR Op. Margin | CGON Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $40M | N/A | -195.5% | N/A | XNCR |
| FY2019 | $160M | N/A | 8.8% | N/A | XNCR |
| FY2020 | $120M | N/A | -62.6% | N/A | XNCR |
| FY2021 | $280M | N/A | 15.9% | N/A | XNCR |
| FY2022 | $160M | N/A | -50.1% | N/A | XNCR |
| FY2023 | $170M | $0M | -75.8% | -27180.9% | XNCR |
| FY2024 | $110M | $0M | -161.5% | -10067.3% | XNCR |
| FY2025 | $130M | $0M | -141.4% | -4722.1% | XNCR |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | XNCR | CGON | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.9B | $6.3B | Larger Scale | CGON |
| Trailing P/E Ratio Valuation | 68.0x | N/M | Lower Multiple | XNCR |
| Forward P/E Ratio Valuation | 68.0x | N/M | Lower Multiple | XNCR |
| Revenue Growth (YoY) Growth | +454.9% | -3.7% | Higher Growth | XNCR |
| Operating Margin (TTM) Profitability | -72.7% | -4293.5% | Higher Margin | XNCR |
| Net Profit Margin Profitability | -58.8% | 0.0% | Higher Margin | CGON |
| Return on Equity (ROE) Capital Efficiency | -19.9% | -28.3% | Higher ROE | XNCR |
| 52-Week Range Position Momentum | 84% ($10โ$41) | 84% ($37โ$94) | Stronger Trend | CGON |
| Beta / 30D Volatility Risk Regime | 1.21ฮฒ ยท 87% Vol | 0.77ฮฒ ยท 86% Vol | Lower Realized Risk | CGON |
| Unified Institutional Score Composite Signal | 29.6 / 100 (SELL) | 45.0 / 100 (HOLD) | Higher Composite | CGON |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full XNCR vs CGON Buy Guide
XNCR
BREAKOUT
58d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
10th %ile
IV Regime
Compressed (<25th %ile)
CGON
CONSOLIDATION
62d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
85th %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither XNCR nor CGON registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.